{"id":"W4281609415","doi":"10.1200/jco.2022.40.16_suppl.tps4619","title":"CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Jewish General Hospital; University of British Columbia; McGill University; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Durvalumab; Bladder cancer; Cystectomy; Oncology; Radiation therapy; Internal medicine; Clinical endpoint; Cancer; Immunotherapy; Population; Chemotherapy; Urology; Randomized controlled trial; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001795105,0.001587598,0.00192651,0.0003881482,0.0005919498,0.0008826737,0.001185008,0.001968644,0.01466206],"category_scores_gemma":[0.001423907,0.0005144211,0.001459681,0.0006220221,0.0007370882,0.0005985164,0.000337023,0.003518284,0.001762926],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003446738,"about_ca_system_score_gemma":0.006006405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02509986,"about_ca_topic_score_gemma":0.09992154,"domain_scores_codex":[0.9994745,0.0002378704,0.00002261977,0.00007965411,0.00006775415,0.0001175565],"domain_scores_gemma":[0.9992338,0.00009848937,0.0001833158,0.00003775594,0.00009277854,0.0003538139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9551654,0.005523964,0.0009726569,0.001282159,0.001034825,0.00004810568,0.00005240206,0.0003320818,0.004602974,0.0002208298,0.007924804,0.02283989],"study_design_scores_gemma":[0.9576352,0.03683339,0.002226364,0.00007774455,0.0004178805,0.00003606892,0.00001748142,0.0002495234,0.000259492,0.00009591339,0.00214078,0.00001022778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9006696,0.01632822,0.001374927,0.004880598,0.001705784,0.03621219,0.02059441,0.0005043676,0.01772996],"genre_scores_gemma":[0.9354008,0.005576463,0.003821384,0.00564479,0.0004816672,0.02082887,0.01332566,0.00007521124,0.01484516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02509986,"threshold_uncertainty_score":0.04990751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.132876920244436,"score_gpt":0.4888937680684552,"score_spread":0.3560168478240192,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}